Figure 4
Effect of 24 h ciGEnC treatments with 5% active and inactive LN or HC sera in IL-1β and IL-6 secretion. IL-1β levels in active and inactive LN patient and HC sera (a) and IL-1β levels in ciGEnC conditioned media (b). IL-6 levels in active and inactive LN patient and HC sera (c) and IL-6 levels in ciGEnC conditioned media (d). Data presented as median concentrations (pg/ml) [range] are analysed using Kruskal-Wallis test with Dunn’s post-hoc test. *P </= 0.05, **P < 0.01 vs HC or vs untreated ciGEnC conditioned media. N = 6/group.
